A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

EGFRvIII gene rearrangement is an early event in glioblastoma tumorigenesis and expression defines a hierarchy modulated by epigenetic mechanisms

(2012) C A Del Vecchio et al.   ONCOGENE

Microvesicles: Messengers and mediators of tumor progression

(2011) Khalid Al-Nedawi et al.   CELL CYCLE

EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway

(2011) R Bonavia et al.   ONCOGENE

Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1

(2010) Roel G.W. Verhaak et al.   CANCER CELL

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma

(2010) M.-d.-M. Inda et al.   GENES & DEVELOPMENT

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

(2010) J. H. Sampson et al.   NEURO-ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells

(2008) Khalid Al-Nedawi et al.   NATURE CELL BIOLOGY